News | MLL

Our newsletter is an offer of MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich (“MLL,” “we”) and contains information about our products and services, research results, events and other news relevant to the company and to the discipline, especially regarding diagnostics and subsequent therapy for leukemia and lymphoma. For you to subscribe, we need the e-mail address that you want us to send the newsletter to. We may use optional information to personalize how the addressee is addressed.
To continuously improve the quality of our newsletter and its contents, we conduct a pseudonymized analysis of the opening rate of the newsletter and information on calling up specific articles. You can find detailed information on how personal data is processed in connection with our newsletter in our Data protection information section.

By clicking on the “Subscribe to the newsletter” button, I consent to allow MLL to use the e-mail address and optional information provided by me for sending the newsletter and for addressing me personally.

You have the right to withdraw your consent at any time. Withdrawing your consent does not affect the lawfulness of the processing that took place based on your consent up until the time of withdrawal. One way you can withdraw your consent is by using the withdrawal function contained in every newsletter. Alternatively, you can declare that you are withdrawing your consent by sending an e-mail to presse@remove-this.mll.com or by mailing a letter to MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich.

Here you will find all MLL News as well as scientific contributions to leukemia diagnostics and research.

to the MLL Magazine

Prof. Dr. med. Dr. phil. Torsten Haferlach
from 08.06.2020
MLL News
Leukemia diagnostics during the pandemic
In the past few months, we have all been confronted with an entirely new situation. Our patients belong to the high-risk group by definition. Hospitals, outpatient clinics, and medical practices have had to be restructured and reorganize their priorities. Workflows had to be re-examined with regard to factual and time-related aspects with hygiene in mind. The goal has been to ensure continued care for patients, while at the same time protecting the employees trained for that very purpose.
Post review
Current rating is 4.2 out of 5

1

2

3

4

5
Read article
Dr. med. Christian Pohlkamp
from 08.06.2020
Diagnostics
Identifying resistance mutations in targeted therapies
Over the past few years, the use of targeted therapies has proven effective for various forms of hematological neoplasia, and increasingly become routine. The rational molecular design of such active substances allows for the targeted blocking of intracellular signal chains in malignant cells, resulting e.g. in cell cycle arrest or ideally apoptosis. Unfortunately, resistance occurs even against such tailored therapies.
Post review
Current rating is 4.0 out of 5

1

2

3

4

5
Read article